Sihuan Pharmaceutical Holdings Group (SZSC:460) - Stock Price, News & Analysis

460 Stock Overview

460 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 21.2% below our estimate of its fair value

Earnings are forecast to grow 117.68% per year

Risk Analysis

No risks detected for 460 from our risk checks.

Sihuan Pharmaceutical Holdings Group Ltd. Competitors

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd

SEHK:1349

HK$6.6b

Consun Pharmaceutical Group

SEHK:1681

HK$4.6b

Tong Ren Tang Technologies

SEHK:1666

HK$6.9b

Beijing Tong Ren Tang Chinese Medicine

SEHK:3613

HK$8.0b

Price History & Performance

Summary of all time highs, changes and price drops for Sihuan Pharmaceutical Holdings Group
Historical stock prices
Current Share Price	HK$0.57
52 Week High	HK$0.83
52 Week Low	HK$0.49
Beta	0.68
1 Month Change	7.55%
3 Month Change	7.55%
1 Year Change	-29.63%
3 Year Change	-80.55%
5 Year Change	-70.16%
Change since IPO	-72.86%

Recent updates

Shareholder Returns

	460	HK Pharmaceuticals	HK Market
7D	7.5%	2.9%	2.6%
1Y	-29.6%	-15.1%	-7.4%

Return vs Industry: 460 underperformed the Hong Kong Pharmaceuticals industry which returned -15.7% over the past year.

Return vs Market: 460 underperformed the Hong Kong Market which returned -8.5% over the past year.

Price Volatility

Is 460's price volatile compared to industry and market?
460 volatility
460 Average Weekly Movement	6.5%
Pharmaceuticals Industry Average Movement	6.2%
Market Average Movement	7.4%
10% most volatile stocks in HK Market	15.0%
10% least volatile stocks in HK Market	3.6%

Stable Share Price: 460 has not had significant price volatility in the past 3 months.

Volatility Over Time: 460's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2001	3,241	Weicheng Guo	www.sihuanpharm.com

Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical and medical aesthetic products in the People’s Republic of China. It offers drugs in the oncology, metabolism, diabetes, cardiovascular and cerebrovascular, modern Chinese medicine, and industrial hemp therapeutic areas. The company is also involved in the investment and sale of medical beauty products; manufacture of medical instruments; investment in properties; construction for medical projects; and project preparation for pharmaceutical products manufacturing.

Sihuan Pharmaceutical Holdings Group Ltd. Fundamentals Summary

How do Sihuan Pharmaceutical Holdings Group's earnings and revenue compare to its market cap?
460 fundamental statistics
Market cap	HK$5.29b
Earnings (TTM)	-HK$58.34m
Revenue (TTM)	HK$2.01b

2.6x

P/S Ratio

-90.7x

P/E Ratio

Is 460 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
460 income statement (TTM)
Revenue	CN¥1.86b
Cost of Revenue	CN¥564.90m
Gross Profit	CN¥1.30b
Other Expenses	CN¥1.35b
Earnings	-CN¥54.02m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0058
Gross Margin	69.64%
Net Profit Margin	-2.90%
Debt/Equity Ratio	22.9%

How did 460 perform over the long term?

See historical performance and comparison

460 Stock Overview

Rewards

Risk Analysis

Sihuan Pharmaceutical Holdings Group Ltd. Competitors

SEHK:1349

HK$6.6b

SEHK:1681

HK$4.6b

SEHK:1666

HK$6.9b

SEHK:3613

HK$8.0b

Price History & Performance

Recent News & Updates

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets

Now 20% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes

Recent updates

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets

Now 20% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes

National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical

First half 2023 earnings released: CN¥0.005 loss per share (vs CN¥0.004 profit in 1H 2022)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Sihuan Pharmaceutical Holdings Group Ltd. Announces Huisheng Biopharmaceutical's Drug Semaglutide Injection Obtained Approval for Clinical Trial

Sihuan Pharmaceutical Holdings Group Ltd. Announces Approval of Phase II Clinical Trial Application of Birociclib by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration

Upcoming dividend of HK$0.037 per share at 9.7% yield

Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.044 profit in FY 2021)

Sihuan Pharmaceutical Holdings Group Ltd. Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Less than half of directors are independent

Sihuan Pharmaceutical Holdings Group Ltd. Announces Management Changes

Upcoming dividend of HK$0.037 per share

Sihuan Pharmaceutical Holdings Group Ltd. Declares Special Cash Dividend for the Six Months Ended 30 June 2022, Payable on or Around 13 October 2022

First half 2022 earnings released: EPS: CN¥0.004 (vs CN¥0.065 in 1H 2021)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2022 Results on Aug 30, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Acceptance of Application for Marketing of Xuanzhu Biopharm\U0027s Drug Fulvestrant Injection by Nmpa of China

Upcoming dividend of HK$0.13 per share

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Sihuan Pharmaceutical Obtains Class III Medical Device Registration Certificate from NMPA for Exclusively Distributed Hyaluronic Acid Persnica

Now 20% undervalued

Full year 2021 earnings released: EPS: CN¥0.044 (vs CN¥0.054 in FY 2020)

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, May 24, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2021, Payable on June 14, 2022

Investor sentiment deteriorated over the past week

Now 25% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces First Class I Macromolecule Innovative Drug Her2 Bispecific Antibody Xzp-Km257 Was Approves for Clinical Trails

Investor sentiment improved over the past week

National Medical Products Administration Accepts Biologics License Application of Insulin Aspart Injection, Insulin Aspart 30 Injection and Insulin Aspart 50 Injection of Jilin Huisheng Biopharmaceutical Co., Ltd

Now 22% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces Medical Device Registration Certificate Obtained for Medical Skin Care Gel and Repair Gel

Sihuan Pharmaceutical Holdings Group Ltd. Announces Fondaparinux Sodium Injection Obtained Manufacture Approval

Investor sentiment deteriorated over the past week

First half 2021 earnings released: EPS CN¥0.065 (vs CN¥0.018 in 1H 2020)

Non-Executive Director Jin-ha Kim has left the company

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.016 per share

Sihuan Pharmaceutical Holdings Group Ltd. Announces Obtains Drug Registration Approval in Relation to Caspofungin Acetate for Injection

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Final Cash Dividend for the Year Ended December 31, 2020, Payable on or Around July 15, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Two Special Cash Dividends

Full year 2020 earnings released: EPS CN¥0.054 (vs CN¥0.29 loss in FY 2019)

Sihuan Pharmaceutical Holdings Group Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day high: HK$2.68

Sihuan Pharmaceutical Holdings Group Ltd. Announces Selection of its Pantoprazole Sodium Injection (Panzuoer® 40mg per unit) and Ibuprofen Injection (Falanfen® 4ml: 0.4g, Tenaan® 8ml: 0.8g) in the Fourth Batch of National Drug Centralized Procurement

Sihuan Pharmaceutical Holdings Group Ltd. Announces Cinepazide Maleate Injection Obtain Approval from the National Medical Products Administration

New 90-day high: HK$1.32

Upcoming Dividend of HK$0.035 Per Share

Sihuan Pharmaceutical Holdings Group Ltd.(SEHK:460) dropped from FTSE All-World Index (USD)

First half earnings released

Deputy General Manager recently bought HK$19m worth of stock